322 related articles for article (PubMed ID: 22210083)
1. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis.
Brettschneider J; Libon DJ; Toledo JB; Xie SX; McCluskey L; Elman L; Geser F; Lee VM; Grossman M; Trojanowski JQ
Acta Neuropathol; 2012 Mar; 123(3):395-407. PubMed ID: 22210083
[TBL] [Abstract][Full Text] [Related]
2. Microglial CD68 and L-ferritin upregulation in response to phosphorylated-TDP-43 pathology in the amyotrophic lateral sclerosis brain.
Swanson MEV; Mrkela M; Murray HC; Cao MC; Turner C; Curtis MA; Faull RLM; Walker AK; Scotter EL
Acta Neuropathol Commun; 2023 Apr; 11(1):69. PubMed ID: 37118836
[TBL] [Abstract][Full Text] [Related]
3. Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS.
Gregory JM; McDade K; Bak TH; Pal S; Chandran S; Smith C; Abrahams S
J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):149-157. PubMed ID: 31515300
[TBL] [Abstract][Full Text] [Related]
4. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam.
Geser F; Winton MJ; Kwong LK; Xu Y; Xie SX; Igaz LM; Garruto RM; Perl DP; Galasko D; Lee VM; Trojanowski JQ
Acta Neuropathol; 2008 Jan; 115(1):133-45. PubMed ID: 17713769
[TBL] [Abstract][Full Text] [Related]
5. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
Takeda T
Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544
[TBL] [Abstract][Full Text] [Related]
6. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
7. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
[TBL] [Abstract][Full Text] [Related]
8. β-amyloid triggers ALS-associated TDP-43 pathology in AD models.
Herman AM; Khandelwal PJ; Stanczyk BB; Rebeck GW; Moussa CE
Brain Res; 2011 Apr; 1386():191-9. PubMed ID: 21376022
[TBL] [Abstract][Full Text] [Related]
9. Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology.
Murakami A; Koga S; Sekiya H; Oskarsson B; Boylan K; Petrucelli L; Josephs KA; Dickson DW
Brain Pathol; 2022 Nov; 32(6):e13100. PubMed ID: 35715944
[TBL] [Abstract][Full Text] [Related]
10. TDP-43 pathology and cognition in ALS: A prospective clinicopathologic correlation study.
Prudlo J; König J; Schuster C; Kasper E; Büttner A; Teipel S; Neumann M
Neurology; 2016 Sep; 87(10):1019-23. PubMed ID: 27488596
[TBL] [Abstract][Full Text] [Related]
11. Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment.
Yang W; Strong MJ
Amyotroph Lateral Scler; 2012 Feb; 13(2):178-93. PubMed ID: 22214313
[TBL] [Abstract][Full Text] [Related]
12. Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
Riku Y; Seilhean D; Duyckaerts C; Boluda S; Iguchi Y; Ishigaki S; Iwasaki Y; Yoshida M; Sobue G; Katsuno M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917673
[TBL] [Abstract][Full Text] [Related]
13. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: Evidence for clinico-pathologic subtypes.
Takeuchi R; Tada M; Shiga A; Toyoshima Y; Konno T; Sato T; Nozaki H; Kato T; Horie M; Shimizu H; Takebayashi H; Onodera O; Nishizawa M; Kakita A; Takahashi H
Acta Neuropathol Commun; 2016 Jun; 4(1):61. PubMed ID: 27338935
[TBL] [Abstract][Full Text] [Related]
15. Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC).
Miklossy J; Steele JC; Yu S; McCall S; Sandberg G; McGeer EG; McGeer PL
Acta Neuropathol; 2008 Dec; 116(6):625-37. PubMed ID: 18843496
[TBL] [Abstract][Full Text] [Related]
16. Neuropathology of Speech Network Distinguishes Bulbar From Nonbulbar Amyotrophic Lateral Sclerosis.
Shellikeri S; Keith J; Black SE; Zinman L; Yunusova Y
J Neuropathol Exp Neurol; 2020 Mar; 79(3):284-295. PubMed ID: 31951003
[TBL] [Abstract][Full Text] [Related]
17. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
Geser F; Lee VM; Trojanowski JQ
Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer disease pathology in amyotrophic lateral sclerosis.
Hamilton RL; Bowser R
Acta Neuropathol; 2004 Jun; 107(6):515-22. PubMed ID: 15024584
[TBL] [Abstract][Full Text] [Related]
19. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.
Geser F; Brandmeir NJ; Kwong LK; Martinez-Lage M; Elman L; McCluskey L; Xie SX; Lee VM; Trojanowski JQ
Arch Neurol; 2008 May; 65(5):636-41. PubMed ID: 18474740
[TBL] [Abstract][Full Text] [Related]
20. The frontotemporal syndromes of ALS. Clinicopathological correlates.
Strong MJ; Yang W
J Mol Neurosci; 2011 Nov; 45(3):648-55. PubMed ID: 21809041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
